Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, García-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O, Goschzik T, Pietsch T, Sill M, Pfister SM, Rutkowski S, Richardson S, Hill RM, Williamson D, Bailey S, Schwalbe EC, Clifford SC, Hicks D.
Goddard J, et al.
Acta Neuropathol. 2023 May;145(5):651-666. doi: 10.1007/s00401-023-02566-0. Epub 2023 Apr 4.
Acta Neuropathol. 2023.
PMID: 37014508
Free PMC article.